variant

stratum

≤1.62

1.63 - 2.57

≥2.58

P-value

N = 71

N = 121

N = 333

Age (M ± SD)

59.5 ± 11.0

64.7 ± 11

61.8 ± 12.4

0.01*

Gender (n, %)

Male

47

66.2%

76

62.8%

248

74.5%

0.037*

Female

24

33.8%

45

37.2%

85

25.5%

TMN Stage

I

35

49.3%

54

44.6%

85

25.7%

0.001*

II

19

26.8%

27

22.3%

50

15.1%

III

13

18.3%

34

28.1%

138

41.7%

IV

4

5.6%

6

5.0%

58

17.5%

Differentiation (Diff) (n, %)

well

3

4.2%

6

5.0%

9

2.7%

0.061

moderately

20

28.2%

28

23.1%

50

15.0%

poorly

0

0.0%

7

5.8%

15

4.5%

Un-Diff

0

0.0%

0

0.0%

1

0.3%

unknown

48

67.6%

80

66.1%

258

77.5%

Hepatitis B/C (n, %)

Non B/C

8

11.3%

16

13.2%

72

21.7%

0.175

HBV

31

43.7%

54

44.6%

149

44.9%

HCV

29

40.8%

46

38.0%

100

30.1%

HBV + HCV

3

4.2%

5

4.1%

11

3.3%

GOT (M ± SD)

82.4 ± 71.6

63.3 ± 40.9

87.8 ± 91.5

0.016*

GPT (M ± SD)

76.3 ± 52.2

57.3 ± 37.7

60.1 ± 68.7

0.084

GOT/GPT (M ± SD)

1.19 ± 0.67

1.24 ± 0.61

1.73 ± 1.43

0.001*

Albumin (M ± SD)

3.7 ± 0.5

3.7 ± 0.6

3.5 ± 0.6

0.085

WBC × 10³ (M ± SD)

5 ± 1.7

5.9 ± 4.2

8.5 ± 5.0

0.001*

Platalate × 10³ (M ± SD)

139.5 ± 67.1

148 ± 82.7

183.5 ± 101.8

0.001*

Lymphocyte (M ± SD)

1952.7 ± 716.4

1659.3 ± 1130.2

1086.0 ± 556.3

0.001*

Treat. method

Non-surgical

45

63.4%

83

68.6%

Surgical

26

36.6%

38

31.4%

266

79.9%

0.002*

Survival

Death

39

54.9%

71

58.7%

262

20.1%

Alive

32

45.1%

50

41.3%

71

78.7%

0.001*